Palivizumab prophylaxis, respiratory syncytial virus and subsequent development of asthma

Igde M., Kabasakal H., Ozturk O., Karatekin G., Aygun C.

MINERVA PEDIATRICA, vol.70, no.3, pp.252-259, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 70 Issue: 3
  • Publication Date: 2018
  • Doi Number: 10.23736/s0026-4946.16.04368-1
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.252-259
  • Keywords: Palivizumab, Prevention and control, Asthma, Respiratory syncytial virus infections, PREMATURE-INFANTS, RSV BRONCHIOLITIS, FOLLOW-UP, INFECTION, RIBAVIRIN, ALLERGY, RISK, IGE, CHILDREN, THERAPY
  • Ondokuz Mayıs University Affiliated: Yes


BACKGROUND: Respiratory syncytial virus (RSV) infection is a disease commonly encountered during childhood and it may relapse. An experience in the early childhood would induce asthma development in the future. Palivizumab has a proven efficacy for the RSV prophylaxis so it may prevent asthma. Our aim was to evaluate the possible protective effect of palivizumab on the development of asthma by using the modified Asthma Predictive Index (mAPI).